recombinant human il2  (R&D Systems)

Journal: bioRxiv

Article Title: The Glucose Transporter GLUT3 Controls Regulatory T Cell Function

doi: 10.64898/2026.03.26.714439

Figure Lengend Snippet: (A and B) Relative body weight changes (A) and experimental autoimmune encephalomyelitis (EAE) clinical scores (B) in WT, GLUT1-deficient ( Slc2a1 fl/fl Cd4 Cre ) and GLUT3-deficient ( Slc2a3 fl/fl Cd4 Cre ) mice following immunization with MOG 35-55 peptide emulsified in CFA; means ± SEM of 6-11 mice per cohort. (C) RT-qPCR analysis of Slc2a1 (GLUT1) and Slc2a3 (GLUT3) expression in isolated splenic CD4 + T cells from WT, GLUT1-deficient and GLUT3-deficient mice used in EAE experiments; data are shown as means ± SEM of 4-11 mice. (D and E) Representative flow cytometric analysis of Foxp3 + Treg cells in the central nervous system (CNS) of WT, GLUT1- and GLUT3-deficient mice 20 days after MOG 35-55 immunization (D) , with quantification of Treg cell frequencies and absolute cell numbers (E) ; means ± SEM of 6-11 mice. (F and G) Frequencies of GM-CSF and IL-2-producing CD4 + T cells in the CNS of WT, GLUT1-and GLUT3-deficient mice 20 days after immunization with MOG 35-55 peptide and restimulation with PMA/ionomycin for 5 h (F) , with quantification of total cell numbers of GM-CSF and IL-2 producing CD4 + T cells in the CNS (G) ; means ± SEM of 6-11 mice. Statistical analyses shown in (A, B, C, E, G) were performed using two-way ANOVA. *, p<0.05; **, p<0.01; ***, p<0.001; ns, non-significant.

Article Snippet: FACS-sorted Treg cells were activated on Delta surface 96-well plates (Nunc) with 0.25 ng/mL anti-CD3 (clone 145-2C1) and 1 ng/mL anti-CD28 (clone 37.51; both Bio X Cell), 20 ng/mL recombinant human IL2 and 10 ng/mL murine IL7 for three days at a density of 2×10 6 cells/mL.

Techniques: Quantitative RT-PCR, Expressing, Isolation

Journal: bioRxiv

Article Title: TcrDesign: De novo design of epitope specific full-length T cell receptors

doi: 10.64898/2026.01.15.699824

Figure Lengend Snippet: ( A ) UMAP dimensionality reduction was performed on generated TCRs for two distinct epitopes, utilizing TCR embedding extracted by TcrDesign-B. ( B ) Binding assay of HLA-A*02:01-ELAGIGILTV tetramer to the nine generated TCRs expressing Jurkat cells was analyzed by flow cytometry. Three candidate TCRs ELA-TCR3, ELA-TCR4 and ELA-TCR6 exhibited specific binding to the tetramer. ( C ) Activation markers NFAT and CD69 levels of reporter Jurkat NFAT-ZsGreen cells expressing candidate TCRs ELA-TCR3, ELA-TCR4, ELA-TCR6 and ELApositive TCR after incubation with ELAGIGILTV-pulsed T2 cell for 24 hours, each sample was tested in triplicate. ( D ) The NFAT-ZsGreen signal and CD69 level of ELApositive-TCR and ELA-TCR3 were determined by fluorescence imaging and flow cytometry analysis. ( E ) Engineered Jurkat T cells were co-cultured with T2 cells and serially diluted peptides for 24 h. Co-cultured supernatants were analyzed by ELISA for secreted IL-2. ( F ) TCR-T cells at various E:T ratios were co-cultured with luciferase-transduced T2 cells. The % specific lysis of T2-luciferase (black) and 1ug/mL ELAGIGILTV pulsed T2-luciferase cells (blue) obtained by bioluminescence assay is plotted against multiple E:T ratios. Dots in the figure represents three replicates.

Article Snippet: For 1 x 10 6 T-lymphocytes, 25 μL of Dynabeads coated with anti-CD3 and anti-CD28 antibodies was added to the RPMI 1640 media supplemented with 200U human recombinant IL-2 (#11848-HNAH1-E, Sino Biological).

Techniques: Generated, Binding Assay, Expressing, Flow Cytometry, Activation Assay, Incubation, Fluorescence, Imaging, Cell Culture, Enzyme-linked Immunosorbent Assay, Luciferase, Lysis, ATP Bioluminescent Assay

Journal: Stem Cell Research & Therapy

Article Title: Hypoxic TCs-preconditioned MSCs ameliorate acute lung injury via enhanced Treg recruitment and function through CXCL5/6-CXCR1 axis

doi: 10.1186/s13287-025-04858-6

Figure Lengend Snippet: CXCL5/6 knockdown attenuated the therapeutic benefits of TC supernatant-preconditioned MSCs in humanized ALI mice. A Flow cytometric analysis of CD4 + CD45 + effector T cell distribution in spleen and lung tissues across different treatment groups. N = 8. * p < 0.05, *** p < 0.001, **** p < 0.0001. ns, not significant. B Flow cytometry revealed significant alterations in pulmonary Treg proportion and their CXCR1 expression across treatment groups. N = 8. * p < 0.05, **** p < 0.0001. ns, not significant. C Comparative analysis of lung tissue homogenate cytokine profiles demonstrated differential expression of pro-inflammatory mediators ((IL-6, TNF-α, IL-17 A, IFN-γ), IL-2 and anti-inflammatory IL-10 across treatment groups. N = 8. * p < 0.05, ** p < 0.01. ns, not significant. Normal, irradiation-only mice; Control, PBMCs-only mice; ALI, PBMCs-only ALI mice; MSC, ALI mice treated with PBMCs and MSCs; TC MSC, ALI mice treated with PBMCs and TC supernatant-preconditioned MSCs; siMSC, ALI mice treated with PBMCs and CXCL5/6-knockdown MSCs preconditioned with TC supernatant

Article Snippet: Tregs were simultaneously activated and expanded by supplementing the culture with DynabeadsTM Human T-Activator CD3/CD28 (Thermo Fisher Scientific, #11456D) at a 1:1 bead-to-cell ratio and recombinant human IL-2 (1000 IU/mL; ACROBiosystems, #GMP-L02H14).

Techniques: Knockdown, Flow Cytometry, Expressing, Quantitative Proteomics, Irradiation, Control